查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1189820

抗生物膜傷口敷料市場—增長、趨勢、COVID-19 影響和預測2023-2028

Anti-Biofilm Wound Dressing Market - Growth, Trends, and Forecasts (2023- 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，抗生物膜傷口敷料市場的複合年增長率預計為 9.5%。

主要亮點

  • COVID-19 大流行對抗生物膜傷口敷料市場產生了重大影響，因為大多數醫療機構都忙於管理 COVID-19 患者。 在封鎖的早期階段，擇期手術被推遲，嚴重影響了傷口護理管理。 據報導，在封鎖期間，患者就診人數顯著減少。 根據德國慕尼黑 Ludwig-Maximilians-Universitat 進行的一項研究，由於大流行，約 23% 的慢性傷口患者無法就醫。 此外，約有 10% 的人表示他們避免去看醫生以進行預防。
  • 越來越多地使用遠程醫療來管理慢性和急性傷口，導致市場強勁復甦。 各種醫療保健提供者已經開發了遠程醫療平台，以有效地管理患有急性和慢性傷口的患者。 例如，2021 年 1 月，Wound Pros Inc. 開發了一個遠程醫療平台，用於患者和專業人員之間的交流。 該供應商還發明了一款名為“RITA”的應用程序，可幫助進行新的診斷和傷口測量。
  • 慢性疾病（糖尿病、靜脈疾病、動脈疾病等）造成的未癒合傷口會在傷口表面出現一層細菌污染膜。 預計慢性和急性傷口病例的增加將在預測期內推動市場增長。 美國國家生物技術信息中心2022年6月發表的一項研究發現，全球壓瘡患病率接近12.8%，其中醫院獲得性壓瘡（HAPI）佔8.4%。
  • 此外，全球新興國家醫療保健基礎設施的發展、傷口管理領域的技術發展以及領先公司和醫療保健專業人員為提高傷口護理意識所做的共同努力也在推動市場增長。我們支持增長。 例如，2022 年 2 月，Asep Medical Holdings Inc. 宣布與美國陸軍醫學研究和材料司令部合作開發的抗生物膜/抗炎□技術取得積極成果。
  • 這些是預計在不久的將來推動對先進傷口敷料解決方案（包括抗生物膜產品）的需求的主要因素。 然而，與傷口護理相關的高成本和熟練專業人員的短缺預計將阻礙市場增長。

主要市場趨勢

化工板塊預計在預測期內將顯著增長

  • 化學抗生物膜敷料領域預計將實現強勁增長，這是由於碘和離子銀產品的主要參與者以及慢性病患者數量的增加。 此外，該細分市場主要參與者推出創新產品也是化學抗生物膜敷料產品佔據較大市場份額的原因。 例如，2020 年 11 月，Sanara MedTech 在市場上推出了 BIAKOS 抗菌皮膚和傷口清潔劑。 臨床研究表明，該產品在使用後 72 小時內即可破壞生物膜微生物。
  • 由於糖尿病等疾病的激增，慢性傷口（靜脈性腿部潰瘍、壓力性潰瘍、糖尿病性腿部潰瘍等）的增加也推動了該行業的發展。 根據國際糖尿病聯合會的數據，到 2021 年，全球將有超過 5.37 億成年人患有糖尿病。 到 2030 年底，這一數字預計將超過 6.4 億。 根據發表在 Healogics 上的一篇文章，大約有 700 萬美國人患有慢性傷口，大流行期間截肢人數增加了 50%。
  • 因此，由於創新產品的推出和慢性傷口的日益流行，預計化學抗生物膜傷口敷料部分在預測期內將呈現顯著增長。

預計北美將主導抗生物膜傷口敷料市場

  • 由於技術先進的產品隨時可用以及該地區傷口護理診所數量不斷增加等因素，預計北美將主導該市場。 在美國醫院和門診手術中心等醫療設施中越來越多地使用先進產品是促進北美研究市場增長的關鍵因素之一。 該地區有 3M、B. Braun SE、Convatec Inc.、SmithplusNephew 和 Coloplast Corp 等主要市場參與者，有利的報銷政策也有望推動市場。
  • 傷口處理（包括壓瘡）支出的增加也在推動市場增長。 根據美國醫療保健研究與質量署發表的一篇論文，每年約有 250 萬患者患有壓瘡，在美國，治療單個患者的費用從每名患者 20,900 美元到 151,700 美元不等，並且不斷增加。
  • 此外，該地區發達的基礎設施和美國交通事故的增加也推動了該地區的市場增長。 據美國國家公路交通安全管理局稱，美國的交通事故數量持續上升。 到 2021 年，道路交通事故將導致超過 42,000 人死亡，與 2020 年報告的 38,824 人死亡相比增加了 10.5%。
  • 由於主要市場參與者的存在、傷口管理支出增加以及交通事故增加等因素，預計美國抗生物膜傷口敷料市場將在北美出現顯著增長。

競爭格局

由於多家公司在全球和區域開展業務，因此抗生物膜傷口敷料市場較為分散。

競爭格局包括 Convatec Inc.、SmithplusNephew、URGO、Coloplast Corp.、3M、B. Braun SE、Molnlycke Health Care AB、Imbed Biosciences、Medline Industries LP 和 Integra LifeSciences，這些公司擁有重要的市場份額。包括分析少數知名的國際和本地公司。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 慢性傷口的患病率增加
    • 先進傷口護理創新產品的介紹
    • 手術次數增加
  • 市場製約因素
    • 高產品成本和替代品的使用增加
  • 行業吸引力 - 波特五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模:百萬美元）

  • 按機制
    • 體檢
    • 化學
    • 生物作用
  • 按傷口類型
    • 慢性傷口
      • 糖尿病足潰瘍
      • 壓瘡
      • 下肢靜脈潰瘍
      • 其他慢性傷口
    • 急性傷口
  • 最終用戶
    • 醫院和診所
    • 手術中心
    • 其他最終用戶
  • 按地區細分
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Convatec Inc.
    • SmithplusNephew
    • URGO
    • Coloplast Corp.
    • 3M
    • B. Braun SE
    • Molnlycke Health Care AB
    • Imbed Biosciences
    • Medline Industries, LP
    • Integra LifeSciences

第7章 市場機會與今後動向

簡介目錄
Product Code: 93225

The anti-biofilm wound dressing market is expected to register a CAGR of 9.5% over the forecast period.

Key Highlights

  • The COVID-19 pandemic had a significant impact on the anti-biofilm wound dressing market as the majority of the healthcare facilities were occupied with the management of COVID-19 patients. The elective procedures were postponed during the initial phase of the lockdown, which significantly impacted wound care management. The number of patient visits reported a substantial decline during the lockdown period. According to a study conducted by Ludwig Maximilian University, Munich, Germany, around 23% of patients suffering from chronic wounds were not able to visit physicians due to the pandemic. Moreover, around 10% of respondents avoided doctor visits as a precaution.
  • The increased use of telehealth in the management of chronic and acute wounds was responsible for the strong recovery of the market. Various healthcare providers developed telehealth platforms in order to effectively manage patients suffering from acute and chronic wounds. For instance, in January 2021, Wound Pros Inc. developed a telehealth platform for communication between patients and professionals. The provider also invented an app named "RITA," which helps in new diagnostic and wound measurement.
  • The unhealed wounds caused by chronic diseases (such as diabetes, venous, or arterial disorders) show bacterial contamination film on the wound surface. The growing cases of chronic and acute wounds are expected to drive the growth of the market during the forecast period. According to the research published by National Center for Biotechnology Information in June 2022, the global prevalence of pressure ulcers is close to 12.8%, with hospital-acquired pressure injury (HAPI) accounting for 8.4% of patients.
  • Moreover, the evolving healthcare infrastructure in developing countries across the globe, technological advancements in the field of wound management, and combined initiatives taken by key players and healthcare providers to increase awareness about wound care are also supporting the market's growth. For instance, in February 2022, Asep Medical Holdings Inc. announced positive outcomes related to the Antibiofilm/Anti-inflammatory Peptide Technology developed with the help of United States Army Medical Research and Materiel Command.
  • These are the key factors expected to drive the demand for advanced wound dressing solutions, including anti-biofilm products, in the near future. However, high costs associated with wound care treatment, along with the scarcity of skilled professionals, are anticipated to impede the growth of the market.

Key Market Trends

Chemical Segment is Expected to Witness Significant Growth Over the Forecast Period

  • The chemical anti-biofilm dressing segment is anticipated to register significant growth owing to the presence of key players in the segment with iodine and ionic silver-based products, along with the rising number of patients suffering from chronic diseases. Moreover, the introduction of innovative products by major players in this segment is also responsible for the significant share of chemical anti-biofilm dressing products in the market. For instance, in November 2020, Sanara MedTech launched BIAKOS Antimicrobial Skin and Wound Cleanser in the market. The clinical studies revealed that after the application of the product, it disrupted biofilm microbes within 72 hours.
  • The increasing prevalence of chronic wounds (like venous leg ulcers, pressure ulcers, and diabetic foot ulcers) due to a surge in the prevalence of medical conditions such as diabetes is also augmenting the growth of the segment. According to the International Diabetes Federation, in 2021, more than 537 million adults were suffering from diabetes across the world. The number is likely to surpass 640 million by the end of 2030. According to the article published in Healogics, around 7 million Americans are living with a chronic wound, and it indicated an increase of 50% in amputations during the pandemic.
  • Therefore, the chemical anti-biofilm dressing segment is expected to witness significant growth over the forecast period due to the introduction of innovative products and the increasing prevalence of chronic wounds.

North America is Expected to Dominate the Anti-Biofilm Wound Dressing Market

  • North America is expected to dominate the market owing to factors such as the easy availability of technologically advanced products and the increasing number of wound care clinics in the region. An increase in the usage of advanced products in the healthcare facilities, such as hospitals and ambulatory surgical centers in United States, is among the key factors which contribute to the growth of the market studied in North America. The presence of key market players such as 3M, B. Braun SE, Convatec Inc., Smith+Nephew, and Coloplast Corp in the region, along with favorable reimbursement policies, are also anticipated to drive the market.
  • Increasing expenditure on the management of wounds, including pressure ulcers, is also driving the growth of the market. According to the article published by the Agency for Healthcare Research and Quality, every year, around 2.5 million patients suffer from pressure ulcers, and the cost of individual patient care ranges from USD 20,900-151,700 per patient in United States.
  • The well-developed infrastructure in the region and the increasing number of road accidents in United States are also propelling the growth of the market in the region. According to the National Highway Traffic Safety Administration, the number of road accidents is continuously increasing in United States. Road accidents were responsible for more than 42,000 fatalities in 2021, which reflects a 10.5% increase as compared to 38,824 fatalities reported in 2020.
  • Owing to the factors such as the presence of key market players, increasing expenditure on wound management, and increasing number of road accidents, the US anti-biofilm wound dressing market is anticipated to show significant growth in North America.

Competitive Landscape

The anti-biofilm wound dressing market is moderately fragmented in nature due to the presence of several companies operating globally and regionally.

The competitive landscape includes an analysis of a few international as well as local companies which hold large market shares and are well known, including Convatec Inc., Smith+Nephew, URGO, Coloplast Corp., 3M, B. Braun SE, Molnlycke Health Care AB, Imbed Biosciences, Medline Industries LP, and Integra LifeSciences, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Chronic Wounds
    • 4.2.2 Introduction of Innovative Products in Advanced Wound Care
    • 4.2.3 Surge in the Number of Surgical Procedures
  • 4.3 Market Restraints
    • 4.3.1 High Product Cost Along with the Increasing Utilization of Substitutes
  • 4.4 Industry Attractiveness - Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Mechanism
    • 5.1.1 Physical
    • 5.1.2 Chemical
    • 5.1.3 Biological
  • 5.2 By Wound Type
    • 5.2.1 Chronic Wounds
      • 5.2.1.1 Diabetic Foot Ulcers
      • 5.2.1.2 Pressure Ulcers
      • 5.2.1.3 Venous Leg Ulcers
      • 5.2.1.4 Other Chronic Wounds
    • 5.2.2 Acute Wounds
  • 5.3 By End User
    • 5.3.1 Hospitals and Clinics
    • 5.3.2 Surgical Centers
    • 5.3.3 Other End Users
  • 5.4 By Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Convatec Inc.
    • 6.1.2 Smith+Nephew
    • 6.1.3 URGO
    • 6.1.4 Coloplast Corp.
    • 6.1.5 3M
    • 6.1.6 B. Braun SE
    • 6.1.7 Molnlycke Health Care AB
    • 6.1.8 Imbed Biosciences
    • 6.1.9 Medline Industries, LP
    • 6.1.10 Integra LifeSciences

7 MARKET OPPORTUNITIES AND FUTURE TRENDS